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ABSTRACT
Background: The Goeckerman regimen
remains one of the oldest, most reliable
treatment options for patients with moderate
to severe psoriasis. Goeckerman therapy
currently consists of exposure to ultraviolet B
light and application of crude coal tar. The
details of the procedure can be confusing and
challenging to understand for the first-time
patient or provider.
Objective: To present a freely available online
guide and video on Goeckerman treatment that
explains the regimen in a patient-oriented
manner.
Methods: The Goeckerman protocol used at the
University of California—San Francisco
Psoriasis and Skin Treatment Center as well as
available information from the literature were
reviewed to design a comprehensive guide for
patients receiving Goeckerman treatment.
Results: We created a printable guide and video
resource that covers the supplies needed for
Goeckerman regimen, the treatment procedure,
expected results, how to monitor for adverse
events, and discharge planning.
Conclusion: This new resource is beneficial for
prospective patients planning to undergo
Goeckerman treatment, healthcare providers,
and trainees who want to learn more about this
procedure. Online media and video delivers
material in a way that is flexible and often
familiar to patients.
Keywords: Goeckerman therapy; Patient
education; Psoriasis; Tar; Video guide
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INTRODUCTION
The Goeckerman regimen is a unique
combination therapy of ultraviolet B (UVB)
light and application of crude coal tar (CCT)
for the treatment of psoriasis [1, 2]. First
introduced in 1925, the Goeckerman regimen
remains one of the oldest, most reliable
treatment options for patients with moderate
to severe psoriasis [3]. The advantage in using
tar and phototherapy together is that tar is a
photosensitizer and when combined with UVB
light acts synergistically to produce better
results than either treatment alone [3–5]. In
comparison to other treatment modalities such
as internal biologic agents, oral systemic agents,
and topical medications, Goeckerman therapy
remains extremely effective with relatively few
side effects. This makes Goeckerman regimen
an excellent alternative for patients who may
have previously failed multiple therapies, the
elderly, pregnant patients, children, and the
immunosuppressed [6].
Goeckerman therapy was originally
administered at an inpatient hospital facility
for 24 h a day for multiple days until the
psoriasis cleared [2]. However, patients today
are often treated in an outpatient day care
setting where they return home at the end of
the treatment day with similar results but
significantly reduced cost [6, 7]. Currently,
Goeckerman therapy at the University of
California—San Francisco (UCSF) Psoriasis
Center requires a minimum time commitment
of 4–5 h in the daycare facility for 5 days a week
for 6 weeks for a total of 30 total treatment days
[1]. The major limitation of this therapy is the
time commitment required as patients should
avoid interruption in their therapy, which can
delay complete treatment of their psoriasis
lesions and shorten the remission time.
Nevertheless, almost all Goeckerman patients
have seen significant improvement in their skin
condition over the duration of their therapy.
In a study performed at the University of
California San Francisco (UCSF) Psoriasis and
Day Care Center 100% of patients receiving
Goeckerman over a 12 week period achieved a
75% or greater improvement in their psoriasis
lesions [8]. Another advantage of Goeckerman
is the long period of remission following
completion of therapy, which can last between
8 months to over a year [6, 9]. Studies have also
shown that Goeckerman therapy can
significantly increase patient satisfaction and
improve overall quality of life [10]. In addition,
UCSF has developed a modified Goeckerman
regimen to treat other skin diseases such as
eczema, prurigo nodularis, and pruritus [11, 12].
For the first-time patient or referring
provider the details of the Goeckerman
procedure can be confusing and challenging to
understand. Therefore, the following guide and
online media attempt to deliver the material in
a way that is easily understandable and readily
accessible. Below we will describe supplies for
Goeckerman therapy, evaluation and
preparation, treatment procedure, daily
assessment, discharge planning, and safety
considerations.
METHODS
We reviewed the Goeckerman therapy protocol
used at the UCSF Psoriasis and Skin Treatment
Center. In addition PubMed database was
searched using the term ‘‘psoriasis’’ combined
with the term ‘‘Goeckerman therapy,’’ ‘‘tar
therapy,’’ or ‘‘tar and light therapy’’ to identify
relevant articles to design a comprehensive
guide for patients receiving Goeckerman
treatment.
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This article does not contain any new studies
with human or animal subjects performed by
any of the authors. All photos are printed with
the consent of the subject(s).
RESULTS AND DISCUSSION
Overview
The guide below will cover the supplies needed
for Goeckerman regimen, the treatment
procedure, how to monitor for side effects,
daily assessment, and discharge planning.
Supplies for the Goeckerman Regimen
Tar used for Goeckerman is available in two
forms. CCT, commonly referred to as ‘‘black
tar,’’ is compounded in white petrolatum
ointment or Cetaphil cream (Galderma
Laboratories, L.P.) in concentrations of 2%,
5%, and 10%. Liquor carbonis detergens
(LCD), commonly referred to as ‘‘gold tar,’’ is
compounded in Aquaphor ointment
(Beiersdorf, Inc.), Cetaphil cream, or
VanicreamTM lotion (Pharmaceutical
Specialties, Inc.) as 20% concentration. Topical
steroids include clobetasol propionate 0.05%
ointment, triamcinolone 0.01% ointment, and
desonide 0.05% ointment. Mineral oil is used
for washing topical medications off.
Moisturizing lotion used after therapy consists
of Aquaphilic ointment (Medco Lab Inc.) or
Vanicream. Plastic wrap is used for occlusion
purposes. Gown, gloves, socks, and shower cap
are used for covering the skin (Table 1).
Evaluation and Preparation
Prior to therapy a complete history and physical
examination is performed for each patient to
obtain important information on current and
past medications, response to previous psoriasis
therapies, history of adverse reactions to
sunlight or phototherapy, and severity of itch.
An initial assessment of the skin will help to
determine the degree and severity of psoriasis
involvement and whether patients display
widespread or intense erythema. In cases of
severe psoriasis it is recommended that patients
undergo a cool down period during which
topical corticosteroids will be applied to the
affected areas and occluded with plastic wrap
until the erythema is greatly reduced
(3–14 days) [1, 11]. This is because UV light
and tar preparations have the potential to
worsen acutely inflamed psoriasis (Table 2).
Table 1 Supplies for Goeckerman regimen
Crude coal tar
(2%, 5%, 10%) ‘‘black
tar’’
White petrolatum ointment
Cetaphil cream
Liquor carbonis
detergens
(20%) ‘‘gold tar’’
Aquaphor ointment
Cetaphil cream
Vanicream lotion
Topical corticosteroids Clobetasol propionate 0.05%
ointment
Triamcinolone 0.01% ointment
Desonide 0.05% ointment
Tar removal Mineral oil
Soap
Moisturizing lotion Aquaphilic ointment
Vanicream
Occlusion Plastic wrap
Miscellaneous Gown
Gloves
Socks
Shower cap
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Treatment Procedure
After the cool down procedure (if needed), the
nurse will administer phototherapy in the
morning each day before applying tar to
affected areas of the skin. Narrowband UVB is
most commonly used although broadband
UVB may be used in certain situations where
narrowband UVB is ineffective or not tolerated
by the patient [5, 8]. The initial phototherapy
dose is determined by the patient’s Fitzpatrick
skin type. A nurse will then adjust subsequent
phototherapy dosing according to the patient’s
response and tolerance to phototherapy,
noting any signs of skin burning or itching
(Table 3).
After phototherapy, CCT will be applied to
affected areas of the body and LCD for scalp
involvement. Tar is typically started with the
lowest concentration available and increased
gradually as tolerated by the patient. Some
patients may not tolerate CCT or LCD in
Aquaphor base due to the greasy texture or
alcohol content [11, 13]. For these patients, tar
in Cetaphil cream, a water based
moisturizer-may be substituted. A formulation
of tar compounded with salicylic acid is often
used in areas with greatly thickened plaques to
help reduce the scaling. However, salicylic acid
should be used with caution in patients with
diabetes or gastric ulcers due to the potential for
adverse side effects [14].
Occlusion of topical tar is then performed
with plastic wrap to the body, arms, and legs,
impermeable gloves for the hands, socks for the
feet, and a shower cap for the scalp (Fig. 1).
Topical tar is typically left on the skin for a
minimum of 4–5 h each day. During this time,
patients may read, listen to music, work on a
laptop computer, socialize with other
Goeckerman patients, or participate in group
activities such as meditation, board games, or
cooking (Fig. 2). After the 4–5 h period, the tar is
washed off in the shower with mineral oil and
soap. After Goeckerman therapy is completed at
the daycare center a nurse will apply LCD in
Aquaphor ointment or Cetaphil cream (less
greasy option) to the body before the patient
leaves for home.
Table 2 Evaluation and preparation
Obtain history and physical
Assess for degree and severity of skin involvement
Perform optional cool down period
Table 3 Treatment procedure
Patient checks in at front desk
;
Nurse administers UVB phototherapy
;
Patient asked to undress for tar application
;
Nurse applies CCT to body and extremities and LCD
to the scalp
;
Tar is occluded with plastic wrap
;
Patient dressed in gown with gloves, socks, and shower
cap
;
Therapy continues for 4–5 h
;
Tar is washed off with mineral oil and soap
;
Nurse applies LCD to the body before patient leaves for
home
CCT crude coal tar, LCD liquor carbonis detergens, UVB
ultraviolet B
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Daily Assessment
Each day the patient will be assessed by the care
team consisting of a doctor, fellow, and nurse
for response to Goeckerman treatment. Signs of
skin burn such as redness of the skin, skin
tightness, pain, and rarely blistering may
indicate too high a dose or intolerance to light
therapy [1]. If a burning sensation develops, the
phototherapy dose is either decreased or
phototherapy treatment is not given at all for
that day. Itch is another common concern as
skin irritation may be a sign of sensitivity from
tar or plastic wrap, in which case the
concentration of tar may be decreased or the
wrap may not be applied. Patients are also
encouraged at this time to update their care
team about any change in their medical
conditions that may have occurred or outside
doctor’s visits they may have had (Table 4).
Discharge Planning
Upon completion of the Goeckerman course,
patients will be started on a maintenance
program which may include outpatient
phototherapy three times a week for the first
month with gradual taper and topical
medications to be applied at home. One
month after completion of Goeckerman the
patient will be scheduled for a follow-up visit
with the doctor (Table 5).
Fig. 1 Supplies for Goeckerman regimen. Left side gown,
socks, shower cap. Top row Mineral oil, Aquaphilic
ointment, Vanicream, plastic wrap. Middle row 20% liquid
carbonis detergens in Vanicream lotion, 20% liquid
carbonis detergens in Aquaphor ointment, 5% crude coal
tar in white petrolatum ointment, triamcinolone 0.01%
ointment. Bottom row Desonide 0.05% ointment,
clobetasol propionate 0.05% ointment
Fig. 2 Treatment procedure. a Nurse occluding tar with
plastic wrap. b Patient spends 4–5 h in waiting area during
tar therapy
Table 4 Daily assessment
Team of doctor, fellows, and nurses evaluate patient
response to treatment
Check for signs of skin burn and itch
Adjust phototherapy dosing and tar concentration as
appropriate
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Safety Considerations
The safety profile of Goeckerman therapy is
excellent with relatively few side effects. One of
the main concerns regarding coal tar is the
theoretical carcinogenic potential. However,
many studies including a review of 13,200
patients undergoing Goeckerman regimen for
psoriasis and eczema showed that there is no
increased riskof cancerwith tar therapycompared
to topical corticosteroids [13]. In addition,
Goeckerman therapy is entirely topical and has
limited internal absorption, so it doesnot increase
the risk for cardiovascular disease, tuberculosis, or
serious infections that may be associated with
some oral or injectable medications [15]. The
most commonly observed side effects include
mild folliculitis, a skin condition characterized by
itchy red bumps that develop around hair
follicles, and mild skin burning from the UVB
light [1]. For this reason it is recommended that
patients avoid extended periods of sun exposure
when tar is applied at home (Table 6).
CONCLUSIONS
Goeckerman therapy is both safe and effective for
treatmentofmoderate to severepsoriasis and is an
excellent treatment option. Nevertheless,
Goeckerman therapy requires a firm time
commitment by the patient. Patients are
encouraged to fully participate in this program
by showing up daily, not missing therapy
sessions, and communicating any symptoms or
concerns to the care staff. With consistent
adherence to therapy, the vast majority of
patients can achieve total body clearing, even in
the toughest areas such as the scalp, palms, and
soles. This guide and the corresponding online
video serves to orient and educate prospective
patients planning to startGoeckerman treatment,
healthcare providers, and trainees who want to
learn more about this procedure.
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Table 5 Discharge planning
Home maintenance program with outpatient
phototherapy, LCD, and topical steroids
Reassess patient response to therapy after 1 month
LCD liquor carbonis detergens
Table 6 Safety considerations
Side effect Signs/symptoms
Skin burninga Redness, tenderness, pain, tightness,
itching, rarely blistering
Noticeable 4–6 h after treatment with
UVB phototherapy
Folliculitis Itchy red bumps that develop around
hair follicles
Itching Skin irritation from tar or occlusion
UVB ultraviolet B
a Patients should avoid extended periods of sun exposure
when tar is applied at home
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